US2008187938A1PendingUtilityA1
ALDH1 As A Cancer Stem Cell Marker
Est. expirySep 22, 2026(~0.2 yrs left)· nominal 20-yr term from priority
G01N 33/57535G01N 33/57515C12N 5/0693G01N 2333/90203
45
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.
Claims
exact text as granted — not AI-modified1 . A method of detecting solid tumor stem cells comprising;
a) contacting a tissue sample with an antibody or antibody fragment configured to detect ALDH1 expression in cells in said tissue sample; and b) determining if said tissue sample contains solid tumor stem cells based on the presence or absence of ALDH1 expression in said tissue sample.
2 . The method of claim 1 , wherein said tissue sample comprises breast cancer cells.
3 . The method of claim 1 , wherein said tissue sample comprises colon cancer cells.
4 . The method of claim 1 , wherein said tissue sample comprises inflammatory breast cancer cells.
5 . The method of claim 1 , wherein said tissue sample is a parafin embedded sample.
6 . The method of claim 1 , further comprising c) determining if said tissue sample contains low levels of BRCRA1 expression.
7 . A method for identifying a cancer patient with a poor prognosis, comprising:
a) obtaining a biological sample from said cancer patient comprising cancer cells; b) treating said biological sample to determine if a portion of said cancer cells are ALDH1 expressing solid tumor stem cells, and c) identifying said cancer patient as having a poor prognosis, wherein said identifying comprises demonstrating the presence of said ALDH1 expressing solid tumor stem cells in said biological sample.
8 . The method of claim 7 , wherein said treating comprises contacting said biological sample with an antibody or antibody fragment specific for ALDH1.
9 . The method of claim 7 , wherein said treating comprises contacting said biological sample with reagents configured to detecting expression of ALDH1 mRNA.
10 . A method for killing or inhibiting the proliferation of solid tumor stem cells comprising contacting said solid tumor stem cells with a biologically effective amount of a composition comprising at least one agent targeted to ALDH1.
11 . The method of claim 10 , further comprising identifying the death of or the prevention of the growth of said solid tumor stem cells following said contacting.
12 . The method of claim 10 , wherein said cell death is apoptosis.
13 . An isolated solid tumor stem cell, wherein: (a) the solid tumor stem cell is derived from a solid tumor; (b) the solid tumor stem cell expresses ALDH1; and (c) the solid tumor stem cell is tumorogenic.
14 . The isolated solid tumor stem cell of claim 13 , wherein (d) the solid tumor stem cell over-expresses ERB2.
15 . The isolated solid tumor stem cell of claim 13 , further wherein: (d) the solid tumor stem cell expresses the cell surface marker epithelial specific antigen (ESA).
16 . The isolated solid tumor stem cell of claim 13 , further wherein: (d) the solid tumor stem cell expresses the cell surface marker epithelial specific antigen (ESA) and CD10.
17 . The isolated solid tumor stem cell of claim 13 , further wherein: (d) the solid tumor stem cell does not expresses the cell surface marker epithelial specific antigen (ESA) or CD10.
18 . The isolated solid tumor stem cell of claim 13 , wherein the solid tumor is a sarcoma cell or an epithelial cancer.
19 . The isolated solid tumor stem cell of claim 13 , wherein the epithelial cancer is a breast cancer or an ovarian cancer.
20 . The isolated solid tumor stem cell of claim 13 , wherein the solid tumor stem cell forms a new tumor upon transplantation into the host animal.Join the waitlist — get patent alerts
Track US2008187938A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.